This company listing is no longer active
tella Past Earnings Performance
Past criteria checks 0/6
Key information
-3.0%
Earnings growth rate
9.7%
EPS growth rate
Life Sciences Industry Growth | 32.0% |
Revenue growth rate | -57.1% |
Return on equity | -6,907.7% |
Net Margin | -1,009.0% |
Last Earnings Update | 31 Mar 2022 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How tella makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 22 | 89 | -898 | 378 | 264 |
31 Dec 21 | 106 | -948 | 431 | 264 |
30 Sep 21 | 123 | -939 | 267 | 409 |
30 Jun 21 | 75 | -696 | 232 | 409 |
31 Mar 21 | 78 | -1,178 | 746 | 409 |
31 Dec 20 | 76 | -1,067 | 642 | 409 |
30 Sep 20 | 77 | -1,131 | 778 | 334 |
30 Jun 20 | 115 | -1,454 | 856 | 334 |
31 Mar 20 | 165 | -958 | 337 | 334 |
31 Dec 19 | 202 | -1,026 | 427 | 334 |
30 Sep 19 | 336 | -880 | 541 | 286 |
30 Jun 19 | 446 | -790 | 640 | 286 |
31 Mar 19 | 466 | -896 | 738 | 286 |
31 Dec 18 | 516 | -929 | 814 | 286 |
30 Sep 18 | 469 | -886 | 700 | 240 |
30 Jun 18 | 511 | -813 | 622 | 240 |
31 Mar 18 | 783 | -633 | 615 | 240 |
31 Dec 17 | 957 | -643 | 571 | 240 |
30 Sep 17 | 1,222 | -1,061 | 843 | 275 |
30 Jun 17 | 1,388 | -980 | 1,011 | 275 |
31 Mar 17 | 1,538 | -1,018 | 1,094 | 275 |
31 Dec 16 | 1,801 | -918 | 1,187 | 275 |
30 Sep 16 | 1,851 | -1,004 | 1,163 | 264 |
30 Jun 16 | 1,868 | -979 | 1,151 | 264 |
31 Mar 16 | 1,813 | -1,014 | 1,207 | 264 |
31 Dec 15 | 1,909 | -990 | 1,223 | 264 |
30 Sep 15 | 1,908 | -644 | 1,150 | 279 |
Quality Earnings: 2191 is currently unprofitable.
Growing Profit Margin: 2191 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2191 is unprofitable, and losses have increased over the past 5 years at a rate of 3% per year.
Accelerating Growth: Unable to compare 2191's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2191 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (49%).
Return on Equity
High ROE: 2191 has a negative Return on Equity (-6907.69%), as it is currently unprofitable.